Patterns of Locoregional Recurrence After Surgery and Radiotherapy or Chemoradiation for Rectal Cancer

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2008 Jan 22

PMID 18207667

Citations 25

Authors

Tse-Kuan Yu

Priya R Bhosale

Christopher H Crane

Revathy B Iyer

John M Skibber

Miguel A Rodriguez-Bigas

Barry W Feig

George J Chang

Cathy Eng

Robert A Wolff

Nora A Janjan

Marc E Delclos

Sunil Krishnan

Prajnan Das

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify patterns of locoregional recurrence in patients treated with surgery and preoperative or postoperative radiotherapy or chemoradiation for rectal cancer.

Methods And Materials: Between November 1989 and October 2001, 554 patients with rectal cancer were treated with surgery and preoperative (85%) or postoperative (15%) radiotherapy, with 95% receiving concurrent chemotherapy. Among these patients, 46 had locoregional recurrence as the first site of failure. Computed tomography images showing the site of recurrence and radiotherapy simulation films were available for 36 of the 46 patients. Computed tomography images were used to identify the sites of recurrence and correlate the sites to radiotherapy fields in these 36 patients.

Results: The estimated 5-year locoregional control rate was 91%. The 36 patients in the study had locoregional recurrences at 43 sites. There were 28 (65%) in-field, 7 (16%) marginal, and 8 (19%) out-of-field recurrences. Among the in-field recurrences, 15 (56%) occurred in the low pelvis, 6 (22%) in the presacral region, 4 (15%) in the mid-pelvis, and 2 (7%) in the high pelvis. Clinical T stage, pathologic T stage, and pathologic N stage were significantly associated with the risk of in-field locoregional recurrence. The median survival after locoregional recurrence was 24.6 months.

Conclusions: Patients treated with surgery and radiotherapy or chemoradiation for rectal cancer had a low risk of locoregional recurrence, with the majority of recurrences occurring within the radiation field. Because 78% of in-field recurrences occur in the low pelvic and presacral regions, consideration should be given to including the low pelvic and presacral regions in the radiotherapy boost field, especially in patients at high risk of recurrence.

Citing Articles

Inter-fraction motion robustness in a prospective phase II trial on dose-escalated proton reirradiation for locally recurrent rectal cancer.

Truelsen C, Ronde H, Kallehauge J, Poulsen L, Havelund B, Pedersen B Phys Imaging Radiat Oncol. 2024; 31:100634.

PMID: 39286771 PMC: 11402650. DOI: 10.1016/j.phro.2024.100634.

Modern Techniques in Re-Irradiation for Locally Recurrent Rectal Cancer: A Systematic Review.

Mantello G, Galofaro E, Bisello S, Chiloiro G, Romano A, Caravatta L Cancers (Basel). 2023; 15(19).

PMID: 37835532 PMC: 10571716. DOI: 10.3390/cancers15194838.

Upper limit of radiation treatment portals in rectal cancer: is it wise to keep using bony landmarks in the present era of 3D conformal treatment?.

Vankina S, Goyal S, Narayanan G Rep Pract Oncol Radiother. 2023; 28(4):565-569.

PMID: 37795231 PMC: 10547415. DOI: 10.5603/RPOR.a2023.0045.

Protocol: The role of defunctioning stoma prior to neoadjuvant therapy for locally advanced colonic and rectal cancer-A systematic review.

Mesri M, Hitchman L, Yiaesemidou M, Quyn A, Jayne D, Chetter I PLoS One. 2022; 17(9):e0275025.

PMID: 36137109 PMC: 9498940. DOI: 10.1371/journal.pone.0275025.

Locally Recurrent Rectal Cancer According to a Standardized MRI Classification System: A Systematic Review of the Literature.

Rokan Z, Simillis C, Kontovounisios C, Moran B, Tekkis P, Brown G J Clin Med. 2022; 11(12).

PMID: 35743581 PMC: 9224654. DOI: 10.3390/jcm11123511.

References

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

Wolmark N, Wieand H, Hyams D, Colangelo L, Dimitrov N, Romond E . Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000; 92(5):388-96. DOI: 10.1093/jnci/92.5.388. View

Pilipshen S, Heilweil M, Quan S, Sternberg S, Enker W . Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer. 1984; 53(6):1354-62. DOI: 10.1002/1097-0142(19840315)53:6<1354::aid-cncr2820530623>3.0.co;2-j. View

Nuyttens J, Kolkman-Deurloo I, Vermaas M, Ferenschild F, Graveland W, de Wilt J . High-dose-rate intraoperative radiotherapy for close or positive margins in patients with locally advanced or recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 2003; 58(1):106-12. DOI: 10.1016/s0360-3016(03)01494-9. View

Willett C, Czito B, Tyler D . Intraoperative radiation therapy. J Clin Oncol. 2007; 25(8):971-7. DOI: 10.1200/JCO.2006.10.0255. View

Das P, Skibber J, Rodriguez-Bigas M, Feig B, Chang G, Hoff P . Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006; 29(3):219-24. DOI: 10.1097/01.coc.0000214930.78200.4a. View

Guerrero Urbano M, Henrys A, Adams E, Norman A, Bedford J, Harrington K . Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006; 65(3):907-16. DOI: 10.1016/j.ijrobp.2005.12.056. View

Kim J, Kim D, Kim T, Park S, Lee S, Shin K . Intensity-modulated radiotherapy with a belly board for rectal cancer. Int J Colorectal Dis. 2006; 22(4):373-9. DOI: 10.1007/s00384-006-0166-x. View

Hocht S, Hammad R, Thiel H, Wiegel T, Siegmann A, Willner J . Recurrent rectal cancer within the pelvis. A multicenter analysis of 123 patients and recommendations for adjuvant radiotherapy. Strahlenther Onkol. 2004; 180(1):15-20. DOI: 10.1007/s00066-004-1130-8. View

10.

Minsky B, Mies C, Recht A, Rich T, Chaffey J . Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer. 1988; 61(7):1408-16. DOI: 10.1002/1097-0142(19880401)61:7<1408::aid-cncr2820610722>3.0.co;2-a. View

11.

Hruby G, Barton M, Miles S, Carroll S, Nasser E, Stevens G . Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: implications for radiotherapy field design. Int J Radiat Oncol Biol Phys. 2002; 55(1):138-43. DOI: 10.1016/s0360-3016(02)03812-9. View

12.

Krook J, MOERTEL C, Gunderson L, Wieand H, Collins R, Beart R . Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991; 324(11):709-15. DOI: 10.1056/NEJM199103143241101. View

13.

Bosset J, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A . Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005; 23(24):5620-7. DOI: 10.1200/JCO.2005.02.113. View

14.

Bosset J, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L . Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355(11):1114-23. DOI: 10.1056/NEJMoa060829. View

15.

Oconnell M, Martenson J, Wieand H, Krook J, Macdonald J, Haller D . Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331(8):502-7. DOI: 10.1056/NEJM199408253310803. View

16.

Gunderson L, SOSIN H . Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer. 1974; 34(4):1278-92. DOI: 10.1002/1097-0142(197410)34:4<1278::aid-cncr2820340440>3.0.co;2-f. View

17.

Kapiteijn E, Marijnen C, Nagtegaal I, Putter H, Steup W, Wiggers T . Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 345(9):638-46. DOI: 10.1056/NEJMoa010580. View

18.

Roeder F, Treiber M, Oertel S, Dinkel J, Timke C, Funk A . Patterns of failure and local control after intraoperative electron boost radiotherapy to the presacral space in combination with total mesorectal excision in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007; 67(5):1381-8. DOI: 10.1016/j.ijrobp.2006.11.039. View

19.

Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U . Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005; 23(24):5644-50. DOI: 10.1200/JCO.2005.08.144. View

20.

Freedman G, Meropol N, Sigurdson E, Hoffman J, Callahan E, Price R . Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007; 67(5):1389-93. DOI: 10.1016/j.ijrobp.2006.11.017. View